This comparative effectiveness study assesses the risk of all-cause mortality, cardiovascular mortality, all-cause hospitalization, and heart failure hospitalization among patients with heart failure with reduced ejection fraction requiring dialysis who receive combined sacubitril-valsartan vs angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. Here, ACE is linked to heart failure.